Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 10/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 6/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656137 | 0.88 | KIF11 (0.53) | PLA2G7KIF11AR | |
| SCHEMBL24385867 | 0.87 | PLA2G7 (0.43) | PLA2G7KIF11AR | |
| SCHEMBL17884205 | 0.87 | PLA2G7 (0.53) | PLA2G7 | |
| SCHEMBL24385774 | 0.85 | HTR2A (0.46) | PLA2G7HTR2ASLC6A4KCNH2AR | |
| SCHEMBL14656344 | 0.84 | KIF11 (0.51) | HTR2ASLC6A4KCNH2KIF11AR | |
| SCHEMBL24030755 | 0.84 | PLA2G7 (0.43) | PLA2G7KIF11 | |
| SCHEMBL30025685 | 0.84 | PLA2G7 (0.43) | PLA2G7KIF11 | |
| SCHEMBL15814682 | 0.84 | AR (0.61) | AR | |
| SCHEMBL875984 | 0.82 | AR (0.53) | PLA2G7HTR2ASLC6A4KCNH2KIF11 | |
| SCHEMBL14656203 | 0.82 | SOS1 (0.40) | HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239135-B1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-09-29 | — | — | US | disclosed |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-15 | — | — | US | disclosed |
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-07 | — | — | US | disclosed |
| EP-3239135-A1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239135-A1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016180247-A1 | BICYCLIC COMPOUND USED AS AN LP-PLA2 INHIBITOR, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 中国科学院上海药物研究所 | 2016-11-17 | — | — | WO | disclosed |
| WO-2016101927-A1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | 中国科学院上海药物研究所 | 2016-06-30 | — | — | WO | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2736908-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | Glaxo Group Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | PLA2G7 1/4885HTR2A 1584/4885SLC6A4 3984/4885 |
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | PLA2G7 9/4885HTR2A 668/4885SLC6A4 2636/4885 |
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | PLA2G7 9/4885HTR2A 668/4885SLC6A4 2636/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | PLA2G7 2/4885HTR2A 1815/4885SLC6A4 4617/4885 |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | PLA2G12B, PLA2G1B, PLA2G4A | PLA2G7 9/4885HTR2A 668/4885SLC6A4 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.